TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial

Danish RCT (n=93) reports in patients with chemorefractory metastatic colorectal cancer, TAS-102 plus bevacizumab was associated with a significantly improved progression-free survival vs TAS-102 monotherapy (4.6 vs 2.6 months respectively, HR 0.45 [95% CI 0.29–0.72]; p=0.0015).

SPS commentary:

In a related editorial, the author notes the uniqueness of this setting in that anti-VEGF therapy with aflibercept and ramucirumab in the second-line setting, and regorafenib in the refractory setting, are not approved in Denmark, and therefore, treatment with TAS-102 (trifluridine/tipiracil) combined with bevacizumab is likely to be beneficial in this population with limited recourse to other strategies.

The Lancet Oncology

Resource links:

Comment